| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
113,340,000 |
| Market
Cap: |
122.41(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.6758 - $2.77 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Karyopharm Therapeutics is a pharmaceutical company focused on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Co.'s main asset, XPOVIO® (selinexor), a Selective Inhibitors of Nuclear Export compound, is indicated for use in adult patients with multiple myeloma who have received at least one prior therapy; adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
41,140 |
41,140 |
| Total Buy Value |
$0 |
$0 |
$49,985 |
$49,985 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
255,827 |
267,169 |
312,512 |
975,987 |
| Total Sell Value |
$306,355 |
$315,908 |
$393,256 |
$4,268,294 |
| Total People Sold |
6 |
6 |
6 |
8 |
| Total Sell Transactions |
19 |
22 |
34 |
58 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Poulton Stuart |
EVP, Chief Development Officer |
• – – |
2022-08-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
70,000 |
|
-55% |
|
| Greene Barry E |
Director |
– • – |
2022-08-11 |
4 |
OE |
$1.49 |
$11,250 |
D/D |
7,576 |
13,606 |
|
- |
|
| Paulson Richard A. |
President and CEO |
• • – |
2022-08-04 |
4 |
S |
$4.48 |
$10,367 |
D/D |
(2,314) |
626,477 |
|
29% |
|
| Paulson Richard A. |
President and CEO |
• • – |
2022-07-08 |
4 |
S |
$5.18 |
$10,948 |
D/D |
(2,115) |
628,791 |
|
-1% |
|
| Pakianathan Deepika |
Director |
– • – |
2022-06-10 |
4 |
S |
$6.00 |
$7,844 |
I/I |
(1,307) |
16,673 |
|
19% |
|
| Pakianathan Deepika |
Director |
– • – |
2022-06-09 |
4 |
S |
$6.18 |
$1,307,028 |
I/I |
(211,500) |
16,686 |
|
25% |
|
| Pakianathan Deepika |
Director |
– • – |
2022-06-08 |
4 |
S |
$6.50 |
$2,119,926 |
I/I |
(325,977) |
18,731 |
|
25% |
|
| Paulson Richard A. |
President and CEO |
• • – |
2022-06-07 |
4 |
S |
$5.76 |
$14,642 |
D/D |
(2,542) |
630,906 |
|
20% |
|
| Mason Michael |
EVP, CFO, Treasurer |
• – – |
2022-06-03 |
4 |
S |
$6.04 |
$3,630 |
D/D |
(601) |
138,509 |
|
18% |
|
| Rangwala Reshma |
EVP & Chief Medical Officer |
• – – |
2022-04-29 |
4 |
A |
$0.00 |
$0 |
D/D |
65,000 |
65,000 |
|
- |
|
| Shacham Sharon |
Chief Scientific Officer |
• – – |
2022-03-29 |
4 |
A |
$0.00 |
$0 |
D/D |
60,000 |
958,131 |
|
- |
|
| Paulson Richard A. |
President and CEO |
• • – |
2022-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
288,750 |
661,950 |
|
- |
|
| Mason Michael |
EVP, CFO & Treasurer |
• – – |
2022-02-28 |
4 |
S |
$10.24 |
$24,550 |
D/D |
(2,398) |
139,110 |
|
49% |
|
| Mason Michael |
EVP, CFO & Treasurer |
• – – |
2022-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
88,200 |
141,508 |
|
- |
|
| Mano Michael |
SVP, General Counsel&Secretary |
• – – |
2022-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
63,000 |
63,000 |
|
- |
|
| Frenkel Ran |
EVP, Chief Dev. Officer |
• – – |
2022-02-28 |
4 |
S |
$10.24 |
$17,025 |
D/D |
(1,663) |
168,290 |
|
49% |
|
| Frenkel Ran |
EVP, Chief Dev. Officer |
• – – |
2022-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
68,250 |
169,953 |
|
- |
|
| Kauffman Michael |
Director |
– • – |
2022-02-28 |
4 |
S |
$10.24 |
$63,739 |
I/I |
(6,226) |
898,131 |
|
49% |
|
| Kauffman Michael |
Director |
– • – |
2022-02-28 |
4 |
S |
$10.24 |
$63,739 |
D/D |
(6,226) |
713,757 |
|
49% |
|
| Kauffman Michael |
Director |
– • – |
2022-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
21,000 |
719,983 |
|
- |
|
| Cheng Sohanya Roshan |
Chief Commercial Officer |
• – – |
2022-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
84,000 |
91,500 |
|
- |
|
| Shacham Sharon |
Chief Scientific Officer |
• – – |
2022-02-28 |
4 |
S |
$10.24 |
$63,739 |
I/I |
(6,226) |
713,757 |
|
49% |
|
| Shacham Sharon |
Chief Scientific Officer |
• – – |
2022-02-28 |
4 |
A |
$0.00 |
$0 |
I/I |
21,000 |
719,983 |
|
- |
|
| Shacham Sharon |
Chief Scientific Officer |
• – – |
2022-02-28 |
4 |
S |
$10.24 |
$63,739 |
D/D |
(6,226) |
898,131 |
|
49% |
|
| Mitchener Stephen |
SVP, Chief Business Officer |
• – – |
2022-02-28 |
4 |
A |
$0.00 |
$0 |
D/D |
47,250 |
50,546 |
|
- |
|
592 Records found
|
|
Page 4 of 24 |
|
|
